BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 9257892)

  • 1. Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia.
    Gardiner N; Lawler M; O'Riordan J; DeArce M; Humphries P; McCann SR
    Bone Marrow Transplant; 1997 Aug; 20(3):235-41. PubMed ID: 9257892
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Donor chimaerism is a strong indicator of disease free survival following bone marrow transplantation for chronic myeloid leukaemia.
    Gardiner N; Lawler M; O'Riordan J; De'Arce M; McCann SR
    Leukemia; 1997 Apr; 11 Suppl 3():512-5. PubMed ID: 9209441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of minimal residual disease and persistence of host-type hematopoiesis: a study in 28 patients after sex-mismatched, non-T cell-depleted allogeneic bone marrow transplantation for Philadelphia-chromosome positive chronic myelogenous leukemia.
    Elmaagacli AH; Becks HW; Beelen DW; Stockova J; Bützler R; Opalka B; Schaefer UW
    Bone Marrow Transplant; 1995 Dec; 16(6):823-9. PubMed ID: 8750276
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukemia.
    Mackinnon S; Barnett L; Heller G
    Bone Marrow Transplant; 1996 Apr; 17(4):643-7. PubMed ID: 8722369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloid mixed chimerism is associated with relapse in bcr-abl positive patients after unmanipulated allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Román J; Serrano J; Jiménez A; Castillejo JA; Reina ML; González MG; Rodríguez MC; García I; Sánchez J; Maldonado J; Torres A
    Haematologica; 2000 Feb; 85(2):173-80. PubMed ID: 10681725
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increasing mixed haematopoietic chimaerism after BMT with total depletion of CD4+ and partial depletion of CD8+ lymphocytes is associated with a higher incidence of relapse.
    Serrano J; Román J; Herrera C; Castillejo JA; Navarro JA; Reina ML; González MG; Rodriguez MC; Pascual A; Sánchez J; Torres A
    Bone Marrow Transplant; 1999 Mar; 23(5):475-82. PubMed ID: 10100562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of bcr/abl transcripts by RT-PCR and their colorimetric evaluation in chronic myeloid leukemia patients receiving allogeneic bone marrow transplantation.
    Santini V; Zoccolante A; Bosi A; Guidi S; Saccardi R; Vannucchi AM; Martinazzo G; Bernabei PA; Ferrini PR
    Haematologica; 1996; 81(3):201-7. PubMed ID: 8767524
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring of lineage-specific chimaerism allows early prediction of response following donor lymphocyte infusions for relapsed chronic myeloid leukaemia.
    Gardiner N; Lawler M; O'Riordan JM; Duggan C; De Arce M; McCann SR
    Bone Marrow Transplant; 1998 Apr; 21(7):711-9. PubMed ID: 9578312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
    Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
    Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
    Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
    Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S; Naparstek E; Nagler A; Ackerstein A; Kapelushnik J; Or R
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
    Lin F; Kirkland MA; van Rhee FV; Chase A; Coulthard S; Bungey J; Goldman JM; Cross NC
    Bone Marrow Transplant; 1996 Dec; 18(6):1147-52. PubMed ID: 8971386
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous reconstitution with BCR-ABL-negative haematopoiesis after T cell-depleted allogeneic BMT for CML.
    Serrano J; Román J; Castillejo JA; Sánchez J; Navarro JA; Martín C; Herrera C; Torres A
    Bone Marrow Transplant; 1998 Sep; 22(6):599-601. PubMed ID: 9758352
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Study of FISH, PCR and Cytogenetics on 25 Patients Submitted to Bone Marrow Transplantation (BMT) for Chronic Myelogenous Leukemia (CML); Which Tests can we Use in Routine Analysis Post BMT?
    Palka G; Lawler M; Morizio E; Gardiner N; Stuppia L; De Arce MA; Di Bartolomeo PD; Capodiferro F; Sabatino G; Gatta V; Calabrese G; Cann SR
    Hematology; 1998; 3(3):193-203. PubMed ID: 27416528
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Detection of minimal residual disease after allogeneic bone marrow transplantation in chronic myeloid leukemia].
    Liu Y; Fu J; Yu X; Chang Y; Xue W; Chen S; Lu D
    Zhonghua Xue Ye Xue Za Zhi; 1997 Mar; 18(3):140-2. PubMed ID: 15622775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Minimal residual disease in chronic myeloid leukaemia.
    Cross NC
    Hematol Cell Ther; 1998 Oct; 40(5):224-8. PubMed ID: 9844816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    van Rhee F; Szydlo RM; Hermans J; Devergie A; Frassoni F; Arcese W; de Witte T; Kolb HJ; Niederwiser D; Jacobsen N; Gahrton G; Bandini G; Carreras E; Bacigalupo A; Michallet M; Ruutu T; Reiffers J; Goldman JM; Apperley J; Gratwohl A
    Bone Marrow Transplant; 1997 Oct; 20(7):553-60. PubMed ID: 9337056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular studies of chimerism and minimal residual disease after allogeneic peripheral blood progenitor cell or bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Becks HW; Mobascher A; Stockova J; Trzensky S; Opalka B; Schaefer UW
    Bone Marrow Transplant; 1996 Aug; 18(2):397-403. PubMed ID: 8864452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal residual disease after bone marrow transplantation for chronic myelogenous leukemia and implications for graft-versus-leukemia effect: a review of recent results.
    Miyamura K; Barrett AJ; Kodera Y; Saito H
    Bone Marrow Transplant; 1994 Aug; 14(2):201-9. PubMed ID: 7994233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J; Alvarez MA; Torres A
    Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.